Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL114174

O=C(Nc1ccccc1)c1ccccc1N1CCNCC1.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 8/20 0.58
POLB P06746 2/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CHEK1 O14757 1/20 0.44
MT-CO2 P00403 1/20 0.44
CCNC P24863 1/20 0.44
CDK8 P49336 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KMT2A Q03164 2/20 0.44
SLC2A1 P11166 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetamide SCHEMBL3100541 0.93 BACE1 (0.51) BACE1POLBALDH1A1GAAL3MBTL1
SCHEMBL7841604 0.92 ALDH1A1 (0.54) BACE1POLBALDH1A1GAAL3MBTL1
SCHEMBL29998472 0.85 LMNA (0.55) BACE1POLBALDH1A1GAAL3MBTL1
SCHEMBL27942187 0.82 PRKCI (0.53) BACE1POLBALDH1A1GAACHEK1
SCHEMBL29998676 0.79 BACE1 (0.45) BACE1ALDH1A1GAAL3MBTL1CHEK1
SCHEMBL112712 0.79 ALDH1A1 (0.56) ALDH1A1CHEK1KMT2AMEN1
SCHEMBL9042448 0.78 BACE1 (0.48) BACE1POLBALDH1A1CHEK1MT-CO2
SCHEMBL5564533 0.77 BACE1 (0.44) BACE1CYP1A2CYP2D6
SCHEMBL8623037 0.77 BACE1 (0.51) BACE1ALDH1A1CYP1A2CYP2D6
Trifluoroacetic Acid SCHEMBL7667828 0.76 POLB (0.80) POLBALDH1A1GAASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424858-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-05-14 EP disclosed
US-8362249-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-29 US disclosed
EP-2424858-A1 CXCR3 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-03-07 EP disclosed
WO-2010126851-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273781-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 BACE1 4207/4885POLB 3011/4885ALDH1A1 1720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.